Skip to main content
All articles

TAVR

TAVR in 2026: What Referring Cardiologists Need to Know Before Sending Patients

By Amavita Editorial (AI-assisted) Published August 22, 2026 Updated August 22, 2026 4 min read AI-assisted · pending clinician review

The TAVR Landscape Has Changed Faster Than Most Referral Patterns

Transcatheter aortic valve replacement has moved well beyond the original high-risk surgical population. The data now supports TAVR across the full spectrum of surgical risk, and the procedural volumes reflect it. But referral patterns have not kept pace with the evidence.

Many referring cardiologists still operate on mental models from 2018 or 2019. They think of TAVR as a last resort for patients who cannot tolerate open surgery. They wait too long to refer. They underestimate how much the risk-benefit calculus has shifted.

This matters because timing changes outcomes. A patient referred at the right stage of their disease trajectory has a fundamentally different procedural risk profile than one referred after years of progressive decompensation.

Who Should Be Referred Now vs. Who Gets Referred Now

The current guidelines support TAVR for severe symptomatic aortic stenosis across all surgical risk categories. In practice, that means the referral conversation should happen earlier than most physicians initiate it.

The patients who benefit most from timely referral are those with:

  • Severe aortic stenosis with early symptoms (dyspnea on exertion, reduced exercise tolerance) even when ejection fraction is preserved
  • Moderate-to-severe stenosis with rapid progression on serial echocardiography
  • Asymptomatic severe stenosis with declining exercise performance on stress testing
  • Patients previously deemed too high-risk for surgical AVR who have not been re-evaluated for TAVR

The patients who get referred late are often those in the last category. They were told years ago that surgery was too risky, and no one revisited the conversation when TAVR became available for their risk profile.

What Has Actually Changed in the Procedure

Three developments matter most for referring physicians:

1. Vascular access has gotten smaller. Current-generation delivery systems use 14-16 French sheaths. Vascular complications, historically the most common serious adverse event, have dropped significantly. This changes the risk conversation for patients with peripheral vascular disease who were previously considered poor candidates.

2. Paravalvular leak rates have decreased. Newer valve designs and better sizing protocols using CT-based annular measurements have reduced moderate or greater paravalvular leak to low single digits. This was the main clinical concern that kept many cardiologists cautious about TAVR in intermediate-risk patients.

3. Conduction disturbance management has improved. New pacemaker rates remain a real consideration, but better implantation depth targets and conduction system monitoring have reduced permanent pacemaker rates with several current platforms. Pre-procedural conduction assessment now plays a larger role in valve selection and procedural planning.

The Miami Advantage for Cardiovascular Research

South Florida has a unique position in cardiovascular clinical research that directly benefits patients considering TAVR or other structural heart interventions.

Miami's patient population is among the most diverse in the country. Clinical trials conducted here naturally enroll participants across a broader demographic range, which strengthens the generalizability of the data and gives patients access to next-generation devices before they reach the commercial market.

At Amavita Research Services, we run cardiovascular clinical trials under the leadership of Dr. William O'Neill, one of the most experienced interventional cardiologists in the field. Our site is GCSA-certified and IAOCR-accredited, which means we meet the highest operational standards for data quality and patient safety.

For referring physicians, this means your patients may be eligible for clinical trials evaluating next-generation TAVR platforms, novel heart failure therapies, or advanced peripheral vascular interventions. A referral to our site is not just a procedural referral. It is access to the frontier of cardiovascular medicine.

What to Include in a TAVR Referral

A complete referral accelerates the evaluation timeline and improves the patient experience. The structural heart team needs:

  • Recent transthoracic echocardiogram (within 6 months) with detailed valve assessment
  • Current medication list and relevant comorbidities
  • Prior cardiac catheterization or CT angiography if available
  • Functional status assessment (how far they walk, what limits them)
  • Any prior surgical evaluation or risk assessment

The most useful thing a referring physician can do is not wait for the patient to become symptomatic at rest. By that point, the procedural risk is higher and the recovery trajectory is longer.

The Bottom Line for Referring Physicians

TAVR in 2026 is not the same procedure it was five years ago. The devices are better, the outcomes data is deeper, and the patient population that benefits is broader. The referring physician's role is to recognize candidates earlier and connect them with experienced structural heart teams before decompensation narrows the treatment window.

If you have patients with severe aortic stenosis who have not been evaluated for TAVR, or patients who were previously told they were not candidates, now is the time to revisit that conversation.

Amavita Research Services is a cardiovascular clinical research site in Miami led by Dr. William O'Neill. We are GCSA-certified, IAOCR-accredited, and actively enrolling in structural heart and heart failure trials. To refer a patient or learn about current trial opportunities, visit amavitaresearch.com.

AI-assisted draft generated by Julio G. Martinez-Clark · pending clinician review · last updated August 22, 2026. This article is general health education and is not medical advice. Always discuss treatment decisions with your physician.